1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Welcia Holdings Co., Ltd.

Welcia Holdings Co., Ltd.

WLCGF
Welcia Holdings Co., Ltd.US flagOther OTC
16.41
USD
- -
- -
3.42BMarket Cap
Welcia Holdings Co., Ltd.
WLCGF
(Other OTC)

Recent

price

16.41

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
7,079.29
7,734.11
7,328.07
7,939.43
4,505.67
4,386.91
1,355.02
1,497.67
1,670.35
1,869.81
4,159.5
4,552.61
4,924.86
5,477.2
5,892.51
6,205.1
5,987.44
Revenue per Share
76.65
114.16
122.96
159.64
103.33
95.27
24.43
34.73
41.24
41.81
109.23
134.23
126.98
129.38
128.04
72.23
106.17
Basic EPS, GAAP
36.98
283.87
190.9
-36.18
290.19
71.09
12.43
48.98
51.4
44.93
261.38
153.1
-18.84
193.83
136.36
170.71
- -
Free Cash Flow per Basic Share
6.16
24.13
15.88
19.08
12.46
15.11
5.27
5.92
8.05
10.56
22.08
27.13
30.18
31.12
33.46
35.43
- -
Dividend per Share
417.94
470.46
500.03
640.64
409.84
531.88
139.1
159.18
192.31
223.35
533
640.49
738.13
834.37
938.31
973.07
978.02
Book Value per Share
550.75
703.01
735.06
912.86
546.71
749.94
245.61
264.14
279.29
300.3
693.68
771.54
874.57
919.67
994.37
1,021.14
1,023.23
Tangible Book Value per Share
28
31
37
37
74
82
390
416
416
417
209
209
208
209
207
207
207
Basic Weighted Avg Shares
198,928
238,752
270,816
293,378
334,393
360,797
528,402
623,163
695,268
779,148
868,280
949,652
1,025,947
1,144,278
1,217,339
1,285,005
1,236,907
Sales/Revenue/Turnover
7.48
7.66
8.65
3.92
3.77
3.94
3.55
3.86
4.15
3.73
4.35
4.53
4.19
3.99
3.55
2.83
3.02
Operating Margin (%)
3,162
3,929
4,500
5,339
6,549
7,135
10,283
11,953
13,266
14,496
15,663
16,975
18,961
23,225
24,392
26,248
- -
Depreciation Expense
2,154
3,524
4,544
5,899
7,669
7,835
9,527
14,451
17,166
17,423
22,802
27,999
26,453
27,030
26,451
14,958
21,934
Net Income, GAAP
52.94
47.34
48.38
47.68
33.96
39.44
42.49
37.69
36.08
39.23
36.94
32.4
37.63
39.28
34.7
45.43
37.68
Effective Tax Rate (%)
1.08
1.48
1.68
2.01
2.29
2.17
1.8
2.32
2.47
2.24
2.63
2.95
2.58
2.36
2.17
1.16
1.77
Profit Margin (%)
-4,264
-3,953
-3,880
-4,138
-6,920
716
5,281
8,300
9,302
1,103
6,969
12,841
18,974
26,064
37,120
44,274
40,634
Working Capital
15,507
14,050
10,298
11,101
12,284
11,381
14,447
15,767
28,249
27,872
28,209
33,628
44,556
63,646
59,484
55,788
55,876
LT Debt
26,912
33,229
37,349
42,791
50,275
70,806
103,776
116,231
130,480
143,946
162,416
180,349
207,885
232,383
244,364
254,484
253,879
Total Equity
- -
17.31
20.52
9.63
11.91
10.21
9.5
10.82
11.55
9.54
11.74
13.02
10.4
9.09
8.53
5.88
6.93
Return on Invested Capital (%)
- -
9.47
11.77
13.6
14.96
12.54
13.27
17.36
16.77
13.8
16.03
17.04
13.23
11.19
9.83
5.6
8.02
Return on Capital (%)
- -
26.83
27.54
27.99
28.36
21.13
19.45
23.99
23.47
20.13
22.32
22.87
18.41
16.48
14.37
7.57
11.27
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Feb'24
May'25
Aug'25
ST Debt
23,215
24,430
21,814
LT Borrowings
27,386
26,507
24,746
LT Finance Leases
32,098
31,152
31,130
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
207
207
207
Market Capitalization
- -
- -
495,692

Working Capital

FRC

•

in mil. unless spec.
Feb'24
May'25
Aug'25
Total Current Assets
259,601
265,455
325,744
Cash, Cash Equivalents & STI
30,533
36,457
82,752
Accounts Receivable, Net
63,197
65,555
80,453
Inventories
137,092
144,146
140,121
Total Current Liabilities
222,481
230,301
285,110
Payables & Accruals
- -
- -
- -
ST Debt
23,215
24,430
21,814
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.14%
9.48%
4.14%
Free Cash Flow
-80.3%
-258.08%
25.49%
Net Income, GAAP
9.83%
-5.23%
-43.45%
Sales/Revenue/Turnover
14.03%
8.17%
5.56%
Total Cash Common Dividend
20.71%
9.95%
6.15%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
298,267
312,750
299,443
306,879
1,217,339
2025
304,734
325,851
- -
- -
1,285,005
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
24.56
- -
- -
- -
128.04
2025
13.67
- -
- -
- -
72.23
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
33.46
2025
- -
- -
- -
- -
35.43
2026
- -
- -
- -
- -
- -
Similar Companies
Irwin Naturals Inc. (IWINF)
Upper Street Marketing Inc. (UPPR)
RemeGen Co., Ltd. (9995.HK)
SCYNEXIS, Inc. (SCYX)
Coral Laboratories Limited (CORALAB.BO)
Kissei Pharmaceutical Co., Ltd. (KSPHF)
Business
Welcia Holdings Co., Ltd. operates as a holding company that manages subsidiaries engaged in the retail of pharmaceuticals and related products through a nationwide chain of drugstores in Japan. The company offers prescription drugs and pharmaceuticals; over-the-counter medicines; hygiene care and nursing products; baby supplies; health foods and supplements; cosmetics; household sundries; and food items, primarily serving individual consumers via its extensive store network concentrated in the Kanto region and other areas across Japan. Founded in September 2008 through the merger of Welcia Kanto and Takada Pharmacy, Welcia Holdings is headquartered in Chiyoda-ku, Tokyo, and maintains capital stock of 7,792 million yen with approximately 16,600 employees. In recent developments, the company has pursued aggressive expansion via strategic acquisitions, including Xchange Inc. in March 2024, Towoshiya Pharmacy Co., Ltd. in June 2024, Welpark Co., Ltd. in September 2024, and WELCIA PARTNERS Co., Inc. (formerly TEPCO Partners) in October 2024, alongside full and medium-scale renovations of over 170 stores to enhance profitability. As of December 2025, Tsuruha Holdings Inc. has completed a share exchange, establishing Welcia Holdings as its wholly owned subsidiary as part of a capital and business alliance with AEON Co., Ltd. and Tsuruha, forming Japan's largest drugstore group with combined annual sales exceeding 2 trillion yen.